Navigation Links
Sirius Genomics Announces Change in Leadership
Date:12/9/2009

VANCOUVER, Dec. 8 /PRNewswire/ - Sirius Genomics, a developer of pharmacogenomic diagnostics, announced today that Chris Wagner has been appointed President and Chief Executive Officer, replacing Dr. Brad Popovich.

"We want to thank Brad for his strong leadership as President and CEO over the last four years. Brad has taken the Company from discovery to the commercialization phase in a very short period of time. Brad has also managed to recruit one of the best management teams I have seen in the companion diagnostic space," stated Dr. Heiner Dreismann, member of the Sirius Genomics Board of Directors.

Dr. Popovich will continue as member of Sirius Genomics Board and will continue to assist Mr. Wagner and the Company with the provision of strategic advice and support.

"The Sirius Board of Directors believes that this is the right time to make this transition in the evolution of the Company because we have initiated our validation studies on our Xigris Diagnostic and we are spending more time on commercialization and partnership initiatives. Mr. Wagner's extensive background in global pharmaceutical and diagnostic commercialization and partnering are the skills needed to move the Xigris Diagnostic forward from here. The Sirius Board appreciates the efforts of both Chris and Brad in making this transition so smooth and seamless," stated Dr. Jim McEwen, Chairman of the Board.

Chris Wagner has over 17 years of experience in marketing, sales and business development. Since 2007, Mr. Wagner was Vice President of Business Development at Sirius Genomics. Previously, Mr. Wagner was with Aspreva Pharmaceuticals as the Vice President of Marketing and Vice President of Business Development. Prior to Aspreva, Mr. Wagner was with Eli Lilly as an international service employee working in Europe, North America and Asia with positions based in Toronto, Indianapolis and Boston. Mr. Wagner holds a BSc in Organic Chemistry from the University of British Columbia.

About Sirius Genomics: www.siriusgenomics.com

Sirius Genomics is a drug-enabling company that develops pharmacogenomic (PGx) diagnostics that lead to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The Company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable PGx products that enable better drug treatment. The Company's first product is a genetic predictor of response to treatment for sepsis, a severe blood infection.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

SOURCE Sirius Genomics Inc.


'/>"/>
SOURCE Sirius Genomics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Learn Proven Practices to Measure, Align and Transform at SiriusDecisions Sales and Marketing Summit 2010
2. Dr. Robert Lanza is Featured Guest on Deepak Chopras SIRIUS XM Stars Radio Show
3. Sirius Genomics Announces 2009 Board of Directors
4. Sirius Genomics to Present at Invest Northwest Conference
5. Sirius Genomics Announces New Collaboration with UK Critical Care Genomics Group
6. NeoGenomics To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 18, 2009
7. Complete Genomics publishes in Science on low-cost sequencing of 3 human genomes
8. Clinical Genomics Continues Collaborative Research With CSIRO
9. NeoGenomics to Present at the Rodman & Renshaw Healthcare Investment Conference on September 10, 2009
10. AutoGenomics Invited to Present at Thomas Weisel Partners 2009 Healthcare Conference
11. International Milk Genomics & Human Health Symposium Speaker Program Announced
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... (PRWEB) , ... February 08, 2016 , ... ... p.m. , Location: Baruch S. Blumberg Institute at the Pennsylvania Biotechnology Center of ... Blumberg Institute and The Commonwealth Medical College (TCMC) will hold an open house ...
(Date:2/9/2016)... , ... February 09, 2016 , ... Tunnell Consulting, Inc. ... Based in Paris, he will focus on acquiring new accounts and work closely with ... , “Fred brings to our European clients more than 15 years of ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... for Public Policy for the National Organization for Rare Disorders (NORD). Dorman will ... ensure their voices are heard throughout the drug regulatory review process. , “Adding ...
(Date:2/9/2016)... LONDON , February 9, 2016 ... replace paper and protect IP   E-WorkBook ... will be rolled out in Germany ... and protect valuable IP. Users will be able to search ... or experiment as part of the application, to boost collaboration ...
Breaking Biology Technology:
(Date:2/3/2016)... , February 3, 2016 ... new market research report "Automated Fingerprint Identification System Market ... Latent Search), Application (Banking & Finance, Government, Healthcare, and ... by MarketsandMarkets, the market is expected to be worth ... of 21.0% between 2015 and 2020. The transformation and ...
(Date:2/3/2016)... , Feb. 3, 2016 ... the addition of the "Emotion Detection ... Machine Learning, and Others), Software Tools (Facial ... Areas, End Users,and Regions - Global forecast ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 /PRNewswire/ ... analysis of the bioinformatic market by reviewing the ... computer enabled tools that drive the field forward. ... report to: Identify the challenges and opportunities ... service providers and software solution developers, as well ...
Breaking Biology News(10 mins):